Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties

Contraception

Volumn 67, Issue 2, 2003, Pages 93-99

  Hammond, Geoffrey L ^a   Abrams, Larry S ^b   Creasy, George W ^b   Natarajan, Jaya ^b   Allen, J Glyn ^c   Siiteri, Pentti K ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Pharmac Consultants   (United Kingdom)

^d 327 Buttercup Court ^*  (United States)

Author keywords

Bioavailability; Ethinyl estradiol; Levonorgestrel; Norelgestromin; Sex hormone binding globulin; Testosterone

Indexed keywords

ALBUMIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTIMATE; NORGESTIMATE; ORTHOCYCLEN; PROTEIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PROTEIN BINDING; FEMALE; HUMAN; NORMAL HUMAN; STEADY STATE;

EID: 0037312457     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(02)00473-0     Document Type: Article

References (31)

1. Sulak P., Lippman J., Siu C., Massaro J., Godwin A. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction. Contraception. 59:1999;161-166.
2. Corson S.L. Norgestimate. Clin Obstet Gynecol. 38:1995;841-848.
3. Runnebaum B., Grunwald K., Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250μg of norgestimate/35μg of ethinyl estradiol) results of an open, multicenter study of 59,701 women . Am J Obstet Gynecol. 166:1992;1963-1968.
4. Kafrissen M.E. A norgestimate-containing oral contraceptive review of clinical studies . Am J Obstet Gynecol. 167:1992;1196-1202.
5. Phillips A., Hahn D.W., Klime K.S., McGuire J.L. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception. 36:1987;181-192.
6. Chapdelaine A., Desmarais J.-L., Derman R.J. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil. 34:1989;347-352.
7. Redmond G.P., Olson W.H., Lippman J.S., Kafrissen M.E., Jones T.M., Jorizzo J.L. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris a randomized, placebo-controlled trial . Obstet Gynecol. 89:1997;615-622.
8. Alton K.B., Hetyei N.S., Shaw C., Patrick J.E. Biotransformation of norgestimate in women. Contraception. 29:1984;19-29.
9. Madden S., Back D.J. Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro. J Steroid Biochem Mol Biol. 38:1991;497-503.
10. Wong F.A., Edom R.W., Duda M., et al. Determination of norgestimate and its metabolites in human serum using high-performance liquid chromatography with tandem mass spectrometric detection. J Chromatogr B. 734:1999;247-255.
11. Phillips A., Hahn D.W., McGuire J.L. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin. Steroids. 55:1990;373-375.
12. Siiteri P.K., Murai J.T., Hammond G.L., Nisker J.A., Raymoure W.J., Kuhn R.W. The serum transport of steroid hormones. Recent Prog Horm Res. 38:1982;457-510.
13. Zuo M., Karras D., Humpel M. Influence of protein binding on the metabolic clearance rate of synthetic progestins in the rat liver perfusion model. Arzneimittelforschung. 42:1992;1130-1138.
14. Anderson D.C. Sex-hormone-binding globulin. Clin Endocrinol. 3:1974;69-96.
15. Briggs M.H. Hormonal contraceptives and plasma sex-hormone-binding globulin. Contraception. 12:1975;149-153.
16. El Makhzangy M.N., Wynn V., Lawrence D.M. Sex hormone binding globulin capacity as an index of oestrogenicity in women on oral contraceptive steroids. Clin Endocrinol (Oxf). 10:1979;39-45.
17. Hammond G.L., Langley M.S., Robinson P.A., Nummi S., Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil Steril. 42:1984;44-51.
18. Hammond G.L., Bocchinfuso W.P., Orava M., Smith C.L., van den Ende A., van Enk A. Serum distribution of two contraceptive progestins 3-ketodesogestrel and gestodene . Contraception. 50:1994;301-318.
19. Victor A., Weiner E., Johansson E.D. Sex hormone binding globulin the carrier protein for d-norgestrel . J Clin Endocrinol Metab. 43:1976;244-247.
20. Schwartz U., Hammerstein J. The oestrogenic potency of various contraceptive steroids as determined by their effects on transcortin binding capacity. Acta Endocrinol (Copenh). 76:1974;159-171.
21. Wiegratz I., Jung-Hoffmann C., Gross W., Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception. 58:1998;83-91.
22. Mishell D.R. The pharmacologic and metabolic effects of oral contraceptives. Int J Fertil. 34:(Suppl):1989;21-26.
23. Hammond G.L., Nisker J.A., Jones L.A., Siiteri P.K. Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. J Biol Chem. 255:1980;5023-5026.
24. Hammond G.L., Lähteenmäki P.L.A., Lähteenmäki P., Luukkainen T. Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steroid Biochem. 17:1982;375-380.
25. PPD Development. Validation report: GC/MS analysis of 17α-ethinyl estradiol and norethindrone in human serum and plasma. PPD Pharmaco. Richmond, VA, 1995.
26. Kuhnz W., al-Yacoub G., Fuhrmeister A. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. Contraception. 46:1992;455-469.
27. Boyd R.A., Zegarac E.A., Posvar E.L., Flack M.R. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol. Contraception. 63:2001;71-76.
28. Dunn J.F., Nisula B.C., Rodbard D. Transport of steroid hormones binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma . J Clin Endocrinol Metab. 53:1981;58-68.
29. Grishkovskaya I., Avvakumov G.V., Sklenar G., Doles D., Hammond G.L., Muller Y.A. Crystal structure of human sex hormone-binding globulin steroid transport by a laminar G-like domain . EMBO J. 19:2000;504-512.
30. Kuhnz W., Blode H., Mahler M. Systemic availability of levonorgestrel after single oral administration of norgestimate-containing combination oral contraceptive to 12 young women. Contraception. 49:1994;255-263.
31. Killinger J., Hahn D.W., Phillips A., Hetyei N.S., McGuire J.L. The affinity of norgestimate for uterine progestogen receptors and its direct action on the uterus. Contraception. 32:1985;311-319.